Fast‐acting insulin aspart (fAsp) is a faster‐acting insulin with a more rapid rate of absorption and greater early‐glucose‐lowering effect than conventional insulin (iAsp).
The aim of this study was to assess the postprandial glycemic control in patients with sensor-augmented pump therapy after one month of treatment with fAsp.
Five patients (2males) treated with sensor-augmented pump therapy (at least 6 months prior to the initiation of fAsp) whose age were 41±11 years and basal HbA1c 7,1±0,4%, were included.
Episodes of postprandial hyperglycemia (>140 mg/dL) were analysed before and after one-month treatment with fAsp. Other variables analysed were the area under the curve (AUC) >140 mg/dL, AUC <70 mg/dL, mean glucose and standard deviation (mg/dL), total insulin dose (IU/day) and basal/bolus distribution (%).
Postprandial hyperglycemia episodes (>140 mg/dL) were reduced by 9.1% after one month of treatment with fAsp.
The continuous glucose monitoring results are shown in the following table:
iAsp | fAsp | |
Mean glucose (mg/dL) | 151.8±22.3 | 151.6±11.1 |
Standard deviation (mg/dL) | 53.6±9.0 | 49.4±7.2 |
Total insulin dose (IU/day) | 41.8±19.2 | 41.7±16.4 |
Basal insulin (%) | 44.8±9.0 | 44.8±6.3 |
Bolus insulin (%) | 55.2±9.0 | 55.2±6.3 |
AUC >140 mg/dL | 28.6±15.5 | 25.9±7.9 |
AUC <70 mg/dL | 0.3±0.2 | 0.3±0.3 |
After one-month follow-up with fAsp, hyperglycemia events decreased without increasing the time in hypoglycemia and without changes in the basal/bolus distribution, in patients with sensor-augmented pump therapy.